share_log

John Oyler Sells 30,520 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

Defense World ·  Sep 24, 2022 04:11

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) CEO John Oyler sold 30,520 shares of the company's stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $153.50, for a total value of $4,684,820.00. Following the sale, the chief executive officer now owns 2,070,913 shares of the company's stock, valued at $317,885,145.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

BeiGene Trading Down 3.7 %

BeiGene stock opened at $138.64 on Friday. The stock has a 50-day moving average of $173.46 and a two-hundred day moving average of $167.46. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.35 and a current ratio of 4.54. BeiGene, Ltd. has a one year low of $118.18 and a one year high of $392.30. The stock has a market cap of $14.37 billion, a PE ratio of -6.79 and a beta of 0.65.

Get BeiGene alerts:

BeiGene (NASDAQ:BGNE – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($5.56) EPS for the quarter, missing analysts' consensus estimates of ($4.23) by ($1.33). BeiGene had a negative net margin of 187.65% and a negative return on equity of 38.58%. The business had revenue of $341.57 million during the quarter, compared to analysts' expectations of $297.28 million. On average, research analysts anticipate that BeiGene, Ltd. will post -17.02 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Morgan Stanley decreased their price objective on BeiGene from $300.00 to $293.00 and set an "overweight" rating for the company in a research note on Friday, July 15th. StockNews.com upgraded BeiGene from a "sell" rating to a "hold" rating in a research note on Monday, August 8th. Finally, JPMorgan Chase & Co. restated an "overweight" rating and set a $296.00 price objective on shares of BeiGene in a research note on Tuesday, August 9th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $299.25.

Institutional Investors Weigh In On BeiGene

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Koshinski Asset Management Inc. increased its holdings in shares of BeiGene by 139.6% in the first quarter. Koshinski Asset Management Inc. now owns 242 shares of the company's stock valued at $46,000 after purchasing an additional 141 shares during the period. Steward Partners Investment Advisory LLC acquired a new position in shares of BeiGene in the second quarter valued at about $65,000. Advisors Asset Management Inc. increased its holdings in shares of BeiGene by 26.7% in the first quarter. Advisors Asset Management Inc. now owns 1,244 shares of the company's stock valued at $235,000 after purchasing an additional 262 shares during the period. Desjardins Global Asset Management Inc. increased its holdings in shares of BeiGene by 7.6% in the second quarter. Desjardins Global Asset Management Inc. now owns 1,523 shares of the company's stock valued at $246,000 after purchasing an additional 107 shares during the period. Finally, Laurel Wealth Advisors Inc. acquired a new position in shares of BeiGene in the fourth quarter valued at about $249,000. 51.77% of the stock is currently owned by hedge funds and other institutional investors.

About BeiGene

(Get Rating)

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Recommended Stories

  • Get a free copy of the StockNews.com research report on BeiGene (BGNE)
  • MarketBeat: Week in Review 9/19 – 9/23
  • Why Does Tesla Stock Remain Resilient?
  • Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
  • 2 Semiconductor Stocks To Watch For Reversals
  • Is Costco's Post-Earnings Price Weakness A Good Time To Buy?

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment